Biotech-Focused Hedge Funds Back Talawar’s Fast Moving SPAC Merger
RA Capital, Deep Track and other healthcare investors joined a $225 million PIPE supporting Talawar Therapeutics’ deal with JATT II, which found a merger partner just over two months after its IPO.
Recent Articles